TruScreen Gains Access To India Market

Company Announcement 07 March, 2017

TruScreen Gains Access to India Market

Cervical cancer technology company, TruScreen Limited (NZAX:TRU), has entered into commercial
agreements with Khandelwal Laboratories Pvt Limited ( K.Lab) for the purpose of providing
TruScreen with access to the Indian market.

India is the world’s largest populated market, with approximately 1.3 billion people, of which
approximately 300 million women are of screening age. It accounts for nearly one third of global
deaths from cervical cancer. Lack of access to cervical screening is a major factor in this abnormally
high mortality rate.

Recently, in November 2016, the Government of India (GOI) announced efforts to address this
mortality rate and mandated a national screening programme for cervical cancer for females aged
over 30 years, setting aside substantive budget allowances for cervical cancer screening commencing
in 2017.

In India, and in particular rural India, there is a shortage of trained health professionals, cytologists
and colposcopists. The Ministry of Health and Family Welfare has stated in its operational guidelines
for screening that a ‘’single visit” approach (where screening and treatment is effected in the one
visit) is the preferred approach for cervical cancer screening. In contrast to other highly subjective
methods, TruScreen provides an ideal solution which is objective and real time. As a result,
TruScreen and Khandelwal Laboratories Pvt. Ltd. have taken steps to immediately commence the
evaluation process for inclusion in the GOI screening programme.

TruScreen is already under similar evaluation by several other Governments for use in their public
screening programmes, including in Mexico, China and the Philippines.

CEO of TruScreen, Martin Dillon, commented: “We are delighted to enter into these commercial
agreements with Khandelwal who are a reputable and well-established pharmaceutical and device
supply company based in Mumbai. These agreements cover the distribution of TruScreen into the
public and private sectors and also the likely establishment of in-country manufacturing facilities to
satisfy supply to the GOI. K Lab have over 700 employees with a strong emphasis on sales and the
supply of oncology products to the private and public sectors in India. TruScreen has reacted quickly
to the Indian opportunity and expects to apply additional resources to this project. ”

ENDS
For more information visit www.truscreen.com
Contact:
Martin Dillon, TruScreen Chief Executive Officer
email: martindillon@truscreen.com
About TruScreen:
TruScreen real time cervical cancer technology utilises a digital wand which is placed on the surface
of the cervix to measure electrical and optical signals from the surrounding tissue to identify
precancerous change, or cervical intraepithelial neoplasia (CIN).TruScreen has distribution contracts
in a range of international markets, including China, Latin America, Central Asia, Russia, the Middle
East and Eastern Europe.
About Khandelwal Laboratories
Established in 1945, K Lab manufactures markets and out-licenses patented pharma formulations,
NDDS, Nanotechnology formulations, Niche APIs and Chiral intermediates. K Lab has over 200
patents granted/pending. It has three manufacturing sites. In its new initiate K Lab has entered into
the field of licensing and marketing patented medical devices in India.
Additional Reading:
http://indiatoday.intoday.in/story/govt-to-make-screening-of-oral-cervix-and-breast-cancer-
mandatory-for-30-from-november-2016/1/783976.html

https://in.finance.yahoo.com/news/government-india-makes-oral-breast-093002804.html
-ENDS-